PWMS News Search Results

       

Back to
   Back to PeopleWithMS NewsWire 



March 2009 Off the Wire . . .

 Date

Title

03-02-09
New Award Reinforces Commitment To Research, UK
Are you a postdoctoral researcher investigating a clinical or biomedical aspect of MS? Or does your research focus on the social or economic conditions of MS sufferers? Would you like the opportunity to study at the leading US institution of your choice? Thanks to a new awards initiative launched in conjunction with the educational exchange organisation the Fulbright Commission, the MS Society now offers a scheme which aims to develop the talent of some of Britain's most promising medical researchers.
[read article]
03-03-09
Stem Cell Breakthrough By Mount Sinai Hospital Researcher
In a study to be released on March 1, 2009, Mount Sinai Hospital's Dr. Andras Nagy discovered a new method of creating stem cells that could lead to possible cures for devastating diseases including spinal cord injury, macular degeneration, diabetes and Parkinson's disease. The study, to be published by Nature online, accelerates stem cell technology and provides a road map for new clinical approaches to regenerative medicine.
[read article]
03-04-09
Hookworms In MS Trial
Scientists from The University of Nottingham will study the potential health benefits of parasitic worms as part of a study investigating treatments for people with the autoimmune condition multiple sclerosis (MS).
[read article]
03-04-09
Possible Link Between Epstein-Barr Virus And Progression Of MS
Epstein-Barr virus (EBV), the pathogen that causes mononucleosis, appears to play a role in the neurodegeneration that occurs in persons with multiple sclerosis, researchers at the University at Buffalo and the University of Trieste, Italy, have shown.
[read article]
03-04-09 National MS Awareness Week Highlights Movement To Advance MS Treatment; More Than 130 Clinical Trials Are Under Way
Research to benefit patients with multiple sclerosis is gaining traction through a number of medical, scientific and advocacy efforts, according to the National Multiple Sclerosis Society, which is celebrating National MS Awareness Week on March 2-8, 2009.
[read article]
03-05-09
COPAXONE(R) Approved By The FDA For Patients With A First Clinical Event Suggestive Of Multiple Sclerosis
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for COPAXONE® (glatiramer acetate injection) to include the treatment of patients who have experienced a first clinical episode and have magnetic resonance imaging (MRI) features consistent with multiple sclerosis (MS).
[read article]
03-08-09
Opexa Provides Key Quality Of Life Data On Tovaxin(R) For Multiple Sclerosis
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS) and diabetes, today announced an update on the continuing analysis of the company's Phase IIb TERMS clinical trial (Tovaxin® for Early Relapsing Multiple Sclerosis) for the treatment of MS.
[read article]
03-10-09
National Multiple Sclerosis Society Commends President Obama's Initial Steps In Removing The Bans On Embryonic Stem Cell Research
The National Multiple Sclerosis Society is a driving force in creating a world free of MS. To advance this goal, the Society continues to seek ways to prevent, slow the progression or repair the effects of MS.
[read article]
03-10-09
New U.S. Policy On Stem Cells Applauded By Rockefeller University President
The executive order making federal money once again available for research on human embryonic stem cells will accelerate biomedical research and hopefully bring us closer to cures for some of our most devastating diseases, says Rockefeller University president Paul Nurse.
[read article]
03-10-09
Obama Issues Executive Order To Lift Some Federal Restrictions On Embryonic Stem Cell Research
President Obama on Monday at an event with Democratic and Republican lawmakers is expected to announce that he will reverse restrictions put in place by former President George W. Bush on federal funding for embryonic stem cell research, in keeping with campaign promises to "separate science and politics," the New York Times reports.
[read article]
03-10-09
Congressman Roscoe Bartlett Supports Embryonic Stem Cell Research Without Destroying Embryos
"It is both immoral and scientifically unnecessary to destroy human embryos to obtain embryonic stem cells, so I was disappointed by President Obama's Executive Order today," said Congressman Roscoe Bartlett, who is the only Member of Congress with a PhD in Human Physiology. "I can not support the destruction of innocent human life for the potential benefit of society, especially when I know that it's unnecessary to harm or kill embryos to engage in embryonic stem cell research."
[read article]
03-11-09
CHI Applauds President Obama's Expansion Of Federal Funding For Stem Cell Research
The California Healthcare Institute (CHI) lauded President Barack Obama's Executive Order to allow the National Institutes of Health (NIH) to fund research using embryonic stem cells. The NIH was previously able to fund research only on a very limited number of stem cell lines.
[read article]
03-11-09
NIH To Establish Guidelines For Use Of Embryos Under Obama Stem Cell Policy
As expected, President Obama on Monday issued an executive order reversing former President George W. Bush's restrictions on federal funding for embryonic stem cell research, the Washington Post reports.
[read article]
03-11-09
Editorials, Opinion Pieces Respond To Executive Order Easing Restrictions On Embryonic Stem Cell Research
Newspapers recently published the following editorials and opinion pieces discussing President Obama's decision on Monday to lift some federal restrictions on embryonic stem cell research.
[read article]
03-13-09
Will Obama's Stem Cell Announcement Doom Promising Adult Stem Cell Research?
Adult Stem Cell scientists and businesses are concerned that President Obama's executive order repealing restrictions on Embryonic Stem Cell research will have the unintended consequence of diverting attention and resources away from the promising Adult Stem Cell scientific advances.
[read article]
03-13-09
1000 Young People To Make Views On Stem Cell Research Known, UK
The controversial subject of Stem Cell research will take centre stage as a debate on the topic is held by more than 1000 Key Stage 4 students. The event will be facilitated by company Y Touring Theatre Company, an operation of Central YMCA, and held at the Royal Albert Hall as part of the venue's Learning and Participation department programme. A panel of leading experts will join an audience of young people to discuss the moral and ethical issues surrounding stem cell research.
[read article]
03-15-09
Congressman Burgess Receives Multiple Sclerosis Society's House Legislator Of The Year Award, USA
Congressman Michael Burgess, M.D. (R-Texas), made the following remarks this morning after receiving the Multiple Sclerosis (MS) Society's House Legislator of the Year Award: "I am honored to receive this award and vow to continue my efforts in the cause to find answers to the questions posed by this disease.
[read article]
03-15-09 Sativex Shows Significant Spasticity Improvement, UK
GW Pharmaceuticals has announced plans to submit an application to market its cannabis-based multiple sclerosis (MS) treatment, Sativex, in the UK.This follows the announcement this week of study results, which showed that in nearly three-quarters of people with MS taking a fixed dose of Sativex, there was an improvement of more than 30% in levels of spasticity.
[read article]
03-16-09
MSRC Welcomes Positive Results Of Sativex For Multiple Sclerosis Spasticity Study, UK
Commenting on the Study results Helen Yates, Chief Executive of the Multiple Sclerosis Resource Centre (MSRC) said: "This is very positive news. Spasticity can be one of the most difficult symptoms for people with MS and anything that can help ease this symptom is welcomed.
[read article]
03-18-09
Zenvia Phase III PBA Trial Completes Patient Enrollment
AVANIR Pharmaceuticals (NASDAQ: AVNR) announced that it has completed targeted enrollment of patients into the STAR trial, a confirmatory Phase III trial of Zenvia™ (dextromethorphan / quinidine [DM/Q]) in patients exhibiting signs and symptoms of pseudobulbar affect (PBA).
[read article]
03-21-09
TAU's New Treatment Could Revive Diseased Brain Cells In Multiple Sclerosis Sufferers
If you're of a certain age, you'll remember Buckminster Fuller's distinctive "geodesic domes" - soccer-ball-shaped structures that the late futurist envisioned as ideal human domiciles. Tel Aviv University chemists remember them too - and are now putting them to use in the treatment of multiple sclerosis (MS).
[read article]
03-23-09
Multiple Sclerosis-ID Consensus Meeting In Brussels, 14 May 2009
In 2007 the European MS Platform organized a conference to launch the MSID project. The main objectives of this project, supported by the European Commission, were and still are: the analysis and comparison of MS data collection systems in Europe with the aim of developing and piloting a European Register on MS, and the activation of the European Code of Good Practice on the quality of life for MS patients.
[read article]
03-23-09
First New Mexico Medical Cannabis Producer Approved
The New Mexico Department of Health has approved the first nonprofit in New Mexico to produce medical cannabis for patients in the Department's Medical Cannabis Program. Nonprofits are allowed to produce up to 95 mature plants and seedlings as well as a usable inventory of medical cannabis to meet the needs of patients in the program.
[read article]
03-25-09
Epiphany Biosciences Initiates Program To Assess Valomaciclovir (EPB-348) As Adjunctive Therapy In Multiple Sclerosis (MS)
Epiphany Biosciences announced that the company plans on filing an IND with the Food and Drug Administration (FDA) to study the potential impact of using the antiviral medication valomaciclovir (EPB-348) as an adjunctive therapy in the treatment of multiple sclerosis.
[read article]
03-29-09
Possible Treatment For PML In Tysabri Multiple Sclerosis Partients Under Investigation
Helen Yates, Chief Executive of the Multiple Sclerosis Resource Centre (MSRC) said: "We truly hope that the research leads to a treatment for this very worrying and potentially life threatening condition.
[read article]
03-29-09 Multiple Sclerosis - Bayer Offers New Betaferon(R) Titration Pack
Bayer will launch a titration pack for patients with multiple sclerosis (MS) that is specially designed to make it easier for them to start Betaferon® (interferon beta-1b) therapy. From now on, the titration pack will be available in Germany.
[read article]
03-29-09 Medivir: Epiphany Biosciences Plans On Filing An IND For Valomaciclovir (MIV-606) Targeting MS
Epiphany Biosciences plans on filing an IND at the FDA to study the potential impact of valomaciclovir in patients with multiple sclerosis. Valomaciclovir, (EBP-348, MIV-606) is a compound licensed from Medivir (STO:MVIRB).
[read article]













E-Mail the NewsWire

 with any news items you discover 

 

 

©copyright 2003 PeopleWithMS.com